南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2015年
4期
511-515
,共5页
刘金坤%郝亚娟%黄嘉维%李欣%蔡红兵%彭康
劉金坤%郝亞娟%黃嘉維%李訢%蔡紅兵%彭康
류금곤%학아연%황가유%리흔%채홍병%팽강
结肠癌%SW480%硫利达嗪%细胞凋亡
結腸癌%SW480%硫利達嗪%細胞凋亡
결장암%SW480%류리체진%세포조망
colon cancer%SW480%thioridazine%apoptosis
目的:研究硫利达嗪对结肠癌SW480细胞增殖及凋亡的影响。方法应用5~30μmol/L硫利达嗪处理SW480细胞,MTT法检测细胞增殖抑制率;Hoechst33342细胞核染色法观察细胞凋亡的形态学改变;流式细胞仪检测细胞凋亡率、细胞周期;RT-qPCR分析PDCD4、c-MYC、BCL2、CCND1、CASPASE3、PARP1、CDK4、EIF4A基因表达水平;Western blotting检测AKT、p-AKT、PDCD4蛋白表达水平。结果 MTT结果表明硫利达嗪抑制SW480细胞的增殖,硫利达嗪处理细胞后出现核固缩、染色质凝集和核碎片化等典型的细胞凋亡特征;流式检测表明硫利达嗪诱导G0/G1期阻滞,细胞凋亡增加。RT-PCR结果表明硫利达嗪处理细胞后PDCD4表达上调,CCND1、CDK4、c-MYC、BCL2、CASPASE3、PARP1和EIF4A表达下调。免疫印迹分析结果显示PDCD4蛋白表达上调,p-AKT蛋白表达下调。结论硫利达嗪能够抑制人结肠癌SW480细胞的增殖,并诱导其凋亡,其机制可能与抑制PI3K/AKT信号通路导致PDCD4表达水平升高有关。
目的:研究硫利達嗪對結腸癌SW480細胞增殖及凋亡的影響。方法應用5~30μmol/L硫利達嗪處理SW480細胞,MTT法檢測細胞增殖抑製率;Hoechst33342細胞覈染色法觀察細胞凋亡的形態學改變;流式細胞儀檢測細胞凋亡率、細胞週期;RT-qPCR分析PDCD4、c-MYC、BCL2、CCND1、CASPASE3、PARP1、CDK4、EIF4A基因錶達水平;Western blotting檢測AKT、p-AKT、PDCD4蛋白錶達水平。結果 MTT結果錶明硫利達嗪抑製SW480細胞的增殖,硫利達嗪處理細胞後齣現覈固縮、染色質凝集和覈碎片化等典型的細胞凋亡特徵;流式檢測錶明硫利達嗪誘導G0/G1期阻滯,細胞凋亡增加。RT-PCR結果錶明硫利達嗪處理細胞後PDCD4錶達上調,CCND1、CDK4、c-MYC、BCL2、CASPASE3、PARP1和EIF4A錶達下調。免疫印跡分析結果顯示PDCD4蛋白錶達上調,p-AKT蛋白錶達下調。結論硫利達嗪能夠抑製人結腸癌SW480細胞的增殖,併誘導其凋亡,其機製可能與抑製PI3K/AKT信號通路導緻PDCD4錶達水平升高有關。
목적:연구류리체진대결장암SW480세포증식급조망적영향。방법응용5~30μmol/L류리체진처리SW480세포,MTT법검측세포증식억제솔;Hoechst33342세포핵염색법관찰세포조망적형태학개변;류식세포의검측세포조망솔、세포주기;RT-qPCR분석PDCD4、c-MYC、BCL2、CCND1、CASPASE3、PARP1、CDK4、EIF4A기인표체수평;Western blotting검측AKT、p-AKT、PDCD4단백표체수평。결과 MTT결과표명류리체진억제SW480세포적증식,류리체진처리세포후출현핵고축、염색질응집화핵쇄편화등전형적세포조망특정;류식검측표명류리체진유도G0/G1기조체,세포조망증가。RT-PCR결과표명류리체진처리세포후PDCD4표체상조,CCND1、CDK4、c-MYC、BCL2、CASPASE3、PARP1화EIF4A표체하조。면역인적분석결과현시PDCD4단백표체상조,p-AKT단백표체하조。결론류리체진능구억제인결장암SW480세포적증식,병유도기조망,기궤제가능여억제PI3K/AKT신호통로도치PDCD4표체수평승고유관。
Objective To study the effect of thioridazine on the proliferation and apoptosis of human colorectal cancer SW480 cells. Methods SW480 cells were treated with different concentrations of thioridazine, and MTT assay was used to evaluate the cell inhibition rate. Hoechst 33342 staining was performed to demonstrate the cell morphology changes. Flow cytometry was used to determine the cell apoptosis and cell cycle changes. RT-qPCR was used to detect PDCD4, c-MYC, BCL2, CCND1, CASPASE3, PARP1, CDK4 and EIF4A mRNA expressions, and Western blotting was employed to assay AKT, p-AKT, and PDCD4 protein expression levels. Results MTT results showed that thioridazine inhibits the proliferation of SW480 cells. SW480 cells treated with thioridazine presented with such typical features of apoptosis of karyopyknosis, chromatin condensation and nuclear fragmentation. Flow cytometry showed that thioridazine was a cell cycle-specific drug and caused cell cycle arrest at G1/G0 phase and an increased cell apoptosis rate. Thioridazine treatment of the cells resulted in up-regulated PDCD4 mRNA expression and down-regulated mRNA expressions of CCND1, CDK4, c-MYC, BCL2, CASPASE3, PARP1 and EIF4A, increased PDCD4 protein expression and reduced p-AKT protein expression. Conclusion Thioridazine inhibits the proliferation and induces apoptosis of SW480 cells by up-regulating PDCD4 and inhibiting PI3K/Akt pathway.